Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults With Hypertension

Slide: 10 of 16

Evidence of Benefits: Blood Pressure-Lowering Effects

There were 77 studies that reported a blood pressure outcome for the comparison of ACEIs versus ARBs, and 3 studies that compared the DRI aliskiren with either an ACEI (ramipril) or an ARB (losartan). There was no clear difference in blood pressure-lowering efficacy between ACEIs and ARBs. Data concerning aliskiren were limited. Aliskiren produced a greater reduction in blood pressure compared to ramipril at 12 weeks, with between-group blood pressure (SBP/DBP) differences of -2.7/-1.6 and -2.3/-1.5 mmHg. Aliskiren compared to the ARB losartan demonstrated no significant differences in blood pressure lowering.